

Title (en)

GASTROINTESTINAL GLUTATHIONE PEROXIDASE IN HEPATITIS C VIRUS INFECTIONS

Title (de)

GASTROINTESTINALES GLUTATHIONPEROXIDASE IN HEPATITIS C VIRUSINFEKTIONEN

Title (fr)

PEROXYDASE DE GLUTATHIONE GASTRO-INTESTINALE DE PROTEINE CELLULAIRE HUMAINE COMME CIBLE POUR UNE INTERVENTION MEDICALE CONTRE LES INFECTIONS DUES AU VIRUS DE L'HEPATITE C

Publication

EP 1377833 A2 20040107 (EN)

Application

EP 02730159 A 20020415

Priority

- EP 0204167 W 20020415
- US 28334501 P 20010413

Abstract (en)

[origin: WO02084294A2] The present invention relates to the human cellular protein glutathione peroxidase-gastrointestinal as potential targets for medical intervention against Hepatitis C virus (HCV) infections. Furthermore, the present invention relates to a method for the detection of compounds useful for prophylaxis and/or treatment of Hepatitis C virus infections and a method for detecting Hepatitis C virus infections in an individual or in cells. Also mono- or polyclonal antibodies are disclosed effective for the treatment of HCV infections together with methods for treating Hepatitis C virus infections or for the regulation of Hepatitis C virus production wherein said antibodies may be used.

IPC 1-7

G01N 33/576; **C12Q 1/28**; **C07K 16/00**; **A61P 31/00**; **A61K 39/00**; **C12N 15/00**; **A61K 48/00**; **A61K 39/29**

IPC 8 full level

A61K 31/00 (2006.01); **A61K 38/21** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61P 31/00** (2006.01); **A61P 31/14** (2006.01); **A61P 43/00** (2006.01); **C07K 16/40** (2006.01); **C12N 5/10** (2006.01); **C12N 9/08** (2006.01); **C12N 15/09** (2006.01); **C12P 21/08** (2006.01); **C12Q 1/02** (2006.01); **C12Q 1/28** (2006.01); **G01N 33/15** (2006.01); **G01N 33/50** (2006.01); **G01N 33/573** (2006.01); **G01N 33/576** (2006.01); **A61K 38/00** (2006.01); **A61K 48/00** (2006.01)

CPC (source: EP)

A61K 31/00 (2013.01); **A61P 31/00** (2017.12); **A61P 31/14** (2017.12); **A61P 43/00** (2017.12); **C12N 9/0065** (2013.01); **C12Q 1/28** (2013.01); **C12Y 111/01009** (2013.01); **G01N 33/573** (2013.01); **G01N 33/5767** (2013.01); **A61K 38/00** (2013.01); **A61K 48/00** (2013.01); **A61K 2039/505** (2013.01); **C12N 2501/24** (2013.01); **G01N 2333/18** (2013.01); **G01N 2333/908** (2013.01); **G01N 2500/04** (2013.01)

Citation (search report)

See references of WO 02084294A2

Citation (examination)

- WO 0040241 A2 20000713 - MAXIM PHARM INC [US]
- ROCKEY D.C.: "Hepatic fibrogenesis and hepatitis C.", SEMINARS IN GASTROINTESTINAL DISEASE, vol. 11, no. 2, UNITED STATES, pages 69 - 83, XP008037936
- ICHIKAWA T.; NAKAO K. ET AL: "Geranylgeranylacetone induces antiviral gene expression in human hepatoma cell", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 280, no. 3, 26 January 2001 (2001-01-26), UNITED STATES, pages 933 - 939, XP002250579
- PELICANO LUIS; LI FENGSHENG ET AL: "Retinoic acid enhances the expression of interferon-induced proteins: Evidence for multiple mechanisms of action", ONCOGENE, vol. 15, no. 19, 6 November 1997 (1997-11-06), pages 2349 - 2359

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 02084294 A2 20021024; **WO 02084294 A3 20031030**; AU 2002302535 A1 20021028; CA 2443525 A1 20021024; EP 1377833 A2 20040107; JP 2004533822 A 20041111

DOCDB simple family (application)

EP 0204167 W 20020415; AU 2002302535 A 20020415; CA 2443525 A 20020415; EP 02730159 A 20020415; JP 2002581997 A 20020415